






An Analysis of Exchange Plan Benefits for Certain Medicines

June 2014







## 123 FORMULARIES FROM PLANS REPRESENTING MOST MAJOR ISSUERS

- The analysis includes formularies from plans offered in a zip code in the largest city(s) in each state
- Formularies include:
  - Low-cost silver and bronze plan options
  - Low-cost strategic players (e.g., Blues, Medicaid managed care plans)
  - Additional formularies in states with a high number of silver plan options and very high enrollment
- Silver plan variations available to consumers with income between 100% and 250% of the Federal Poverty Level are not included in this analysis
- Most carriers use similar formularies across metal tiers and network type within a given state

| LID//AIDC               | A - 42 - 2-1-                 | A_E 1107  | NNRTIs                  |
|-------------------------|-------------------------------|---|-------------------------|
| HIV/AIDS                | Antivirals                    | Anti-HIV agents, non-nucleoside reverse transcriptase inhibitors            |                         |
|                         |                               | Anti-HIV agents, nucleoside and nucleotide reverse transcriptase inhibitors | NRTIs                   |
|                         |                               | Anti-HIV agents, protease inhibitors  | Pis                     |
|                         |                               | Anti-HIV agents, other  | HIV-Other <sup>1</sup>  |
| Mental Health           | Antidepressants               | Serotonin/ Norepinephrine reuptake inhibitors                               | SSRIs/SNRIs             |
|                         |                               | Antidepressants, other  | AD-Other                |
|                         | Antipsychotics                | 2 <sup>nd</sup> generation/ atypical  | Atypicals               |
|                         | Bipolar Agents                | Bipolar Agents-Other  | Bipolar-Other           |
| Oncology                | Metabolic Bone Disease Agents | No class  | Bone Disease            |
|                         | Antineoplastics               | Alkylating agents   | Alkylating              |
|                         |                               | Molecular target inhibitors   | MTIs                    |
|                         |                               | Antiangiogenic agents   | Antiangiogenics         |
|                         | Antiemetics                   | Emetogenic Therapy Adjuncts   | Emetogenics             |
| Diabetes                | Blood Glucose Regulators      | Antidiabetic agents   | Antidiabetics           |
|                         |                               | Insulins  | Insulins                |
| Rheumatoid<br>Arthritis | Immunological Agents          | Immune suppressants   | Immunosup               |
| Multiple Sclerosis      | Central Nervous System Agents | Multiple Sclerosis Agents   | MS                      |
| Asthma                  | Respiratory Tract Agents      | Bronchodilators, Sympathomimetic  | B <sub>2</sub> agonists |
|                         |                               | Anti-inflammatories, Inhaled Corticosteroids                                | ICS                     |
|                         |                               |   |                         |